Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-10-16
2007-10-16
Bragdon, Kathleen Kerr (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S183100, C435S069700, C530S391700
Reexamination Certificate
active
10487115
ABSTRACT:
Disclosed herein are modified proaerolysin (PA) peptide. In some examples, the proteins include a prostate-specific protease cleavage site and can further include a prostate-tissue-specific binding domain which functionally replaces the native PA binding domain. In other examples, the proteins include a furin cleavage site and a prostate tissue-specific binding domain which functionally replaces the native PA binding domain. Methods of using such peptides to treat prostate cancer are also disclosed.
REFERENCES:
patent: 5599686 (1997-02-01), DeFeo-Jones et al.
patent: 5677274 (1997-10-01), Leppla et al.
patent: 5777078 (1998-07-01), Bayley et al.
patent: 5798218 (1998-08-01), Buckley
patent: 5817771 (1998-10-01), Bayley et al.
patent: 5824776 (1998-10-01), Bayley et al.
patent: 5858358 (1999-01-01), June et al.
patent: 5866679 (1999-02-01), DeFeo-Jones et al.
patent: 5948750 (1999-09-01), Garsky et al.
patent: 5985877 (1999-11-01), Dionne et al.
patent: 5998362 (1999-12-01), Feng et al.
patent: 6190657 (2001-02-01), Pawelek et al.
patent: 6265540 (2001-07-01), Isaacs et al.
patent: 6331415 (2001-12-01), Cabilly et al.
patent: 6368598 (2002-04-01), D'Amico et al.
patent: 6391305 (2002-05-01), Feng et al.
patent: 6410514 (2002-06-01), Isaacs et al.
patent: 6495315 (2002-12-01), Hildreth et al.
patent: 6504014 (2003-01-01), Isaacs et al.
patent: 6545131 (2003-04-01), Isaacs et al.
patent: 6593095 (2003-07-01), Buckley et al.
patent: 7053042 (2006-05-01), Denmeade et al.
patent: 2002/0041880 (2002-04-01), DeFeo-Jones et al.
patent: 2002/0045736 (2002-04-01), Yu et al.
patent: 2002/0077454 (2002-06-01), Yu et al.
patent: 2005/0266512 (2005-12-01), Buckley
patent: 1 052 287 (2000-11-01), None
patent: 1 052 288 (2000-11-01), None
patent: WO 94/25616 (1994-11-01), None
patent: WO 95/26204 (1995-10-01), None
patent: WO 96/02555 (1996-02-01), None
patent: WO 96/20688 (1996-07-01), None
patent: WO 97/40857 (1997-11-01), None
patent: WO 98/11211 (1998-03-01), None
patent: WO 98/18810 (1998-05-01), None
patent: WO 98/20135 (1998-05-01), None
patent: WO 98/37919 (1998-09-01), None
patent: WO 98/40100 (1998-09-01), None
patent: WO 98/52581 (1998-11-01), None
patent: WO 98/52966 (1998-11-01), None
patent: WO 99/02175 (1999-01-01), None
patent: WO 99/20252 (1999-04-01), None
patent: WO 00/01419 (2000-01-01), None
patent: WO 01/09165 (2001-02-01), None
patent: WO 01/85777 (2001-11-01), None
patent: WO 02/26777 (2002-04-01), None
patent: WO 02/38799 (2002-05-01), None
patent: WO 02/43773 (2002-06-01), None
Walker, B., and Bayley, H., 1994, “A pore-forming protein with a protease-activated trigger”, Protein Engineering, vol. 7, No. 1, pp. 91-97.
Denmeade et al., 2003, “Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer”, Journal of the National Cancer Institute, vol. 95, No. 13, pp. 990-1000.
Williams et al., 2007, “A prostate-specific antigen-activated channel forming toxin as therapy for prostatic disease”, Journal of the National Cancer Institute, vol. 99, No. 5, pp. 376-385.
Protox Therapeutics press release, Jan. 18, 2007, Protox reports promising interim results from prostate cancer therapy:, two pages.
Chen et al., “Glycophosphatidylinositol-Anchored Protein Deficiency as a Marker ofMutatorPhenotypes in Cancer,”Cancer Res. 61:654-658 (2001).
Denmeade et al., “Specific and Efficient Peptide Substrates for Assaying the Proteolytic Activity of Prostate-Specific Antigen,”Cancer Res. 57:4924-4930 (1997).
MacKenzie et al., “Analysis of Receptor Binding by the Channel-Forming Toxin Aerolysin Using Surface Plasmon Resonance,”J. Biol. Chem. 274: 22604-22609 (1999).
Rossjohn et al., “Aerolysin and Pertussis Toxin Share a Common Receptor-Binding Domain,”EMBO J. 16:3426-3434 (1997).
Spyres et al., “Cytosolic Delivery and Characterization of the TcdB Glucosylating Domain by Using a Heterologous Protein Fusion, ”Infection Immun. 69:599-601 (2001).
Tanha et al., “Optimal Design Features of Camelized Human Single-Domain Antibody Libraries,”J. Biol. Chem. 276:24774-24780 (2001).
Abrami et al., “The Pore-Forming Toxin Proaerolysin is Activated by Furin,”J. Biol. Chem. 273:32656-32661 (1998).
Audtho et al., “Production of Chymotrypsin-ResistantBacillus thuringiensisCry2Aa1 δ-Endotoxin by Protein Engineering,”Appl. Environ. Micriobiol. 65:4601-4605 (1999).
Ballard et al., “The Primary Structure ofClostridium septicumAlpha-Toxin Exhibits Similarity with That ofAeromonas hydrophilaAerolysin,”Infect. Immun. 63:340-344 (1995).
Gordon et al., “Clostridium septicumAlpha-Toxin Is Proteolytically Activated by Furin,”Infect. Immun. 65:4130-4134 (1997).
Pang et al., “Activation and Fragmentation ofBacillus thuringiensisδ-Endotoxin by High Concentrations of Proteolytic Enzymes,”Can. J. Microbiol. 45:816-825 (1999).
Correale et al., “Generation of Human Cytolytic T Lymphocyte Lines Directed Against Prostate-Specific Antigen (PSA) Employing a PSA Oligoepitope Peptide,”J. Immunol. 161:3186-3194 (1998).
Gong et al., “Overview of Evolving Strategies Incorporating Prostate-Specific Membrane Antigen as Target for Therapy,”Mol. Urol. 4:217-222 (2000).
Rosen et al. “Enzymatic Activation of a Modified Proaerolysin Toxin by Prostate-Specific Antigen (PSA) as Treatment for Prostate Cancer,”Proceedings of the American Association for Cancer Research Annual Meeting 43:92 (2002).
Buckley James Thomas
Denmeade Samuel R.
Isaacs John T.
Bragdon Kathleen Kerr
Johns Hopkins University
Klarquist & Sparkman, LLP
Moore William W.
University of Victoria Innovation and Development Corporation
LandOfFree
Proaerolysin containing protease activation sequences and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Proaerolysin containing protease activation sequences and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Proaerolysin containing protease activation sequences and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3863056